Ogier has assisted Medicxi Ventures, formerly Index Ventures Life Sciences, with its formation as an independent life sciences firm. Medicxi Ventures comprises all of the existing life sciences portfolio companies, funds and team from Index Ventures.
The Ogier team also worked with Medicxi Ventures on the establishment of Medicxi Ventures I, a new fund focused on early-stage life sciences investments in Europe, which has raised 210 million euros with GlaxoSmithKline and Johnson & Johnson Innovation-JJDC Inc. The closing of Medicxi Ventures I consolidates the position of Medicxi Ventures as one of the largest life sciences focused venture firms in Europe.
"We are doubling down on life sciences and early-stage investments across Europe," says general partner Francesco De Rubertis, who expects 80 to 90 percent of Medicxi investments to be in Europe.
Partner Niamh Lalor led the Ogier Jersey team assisted by senior associate Joanna Christensen and associate Tara Kapur.
Lalor says: "We were delighted to be involved in this transaction and to have the opportunity to work with a new fund manager of this calibre. We wish Medicxi Ventures all the best."
